[1]李焰梅,郝丹,蒋献.大麻二酚在皮肤科的研究进展[J].中国皮肤性病学杂志,2019,(10):1202-1205.[doi:10.13735/j.cjdv.1001-7089.201901008]
 LI Yanmei,HAO Dan,JIANG Xian.Research Progress of Cannabidiol in Dermatology[J].The Chinese Journal of Dermatovenereology,2019,(10):1202-1205.[doi:10.13735/j.cjdv.1001-7089.201901008]
点击复制

大麻二酚在皮肤科的研究进展
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2019年10期
页码:
1202-1205
栏目:
综述
出版日期:
2019-09-13

文章信息/Info

Title:
Research Progress of Cannabidiol in Dermatology
文章编号:
1001-7089(2019)10-1202-04
作者:
李焰梅郝丹蒋献
四川大学华西医院皮肤性病科,四川 成都 610041
Author(s):
LI YanmeiHAO DanJIANG Xian
(Department of Dermatology,West China Hospital,Sichuan University,Chengdu 610041,China)
关键词:
大麻二酚 药物靶点 痤疮 银屑病 皮炎 黑素瘤
Keywords:
Cannabidiol Drug targets Acne Psoriasis Dermatitis Melanoma
分类号:
R 751
DOI:
10.13735/j.cjdv.1001-7089.201901008
文献标志码:
A
摘要:
大麻二酚(cannabidiol,CBD)是工业大麻中含量最丰富的大麻素,其不具有精神活性,基本无毒副作用,目前已被FDA批准用于治疗难治性癫痫,并且在炎症性以及增殖性疾病中显示出良好的治疗作用。近年来研究表明CBD在皮肤科具有良好的应用前景,可能有益于痤疮、皮炎、银屑病和皮肤肿瘤等疾病。因此,本文主要综述CBD的作用靶点及其在多种皮肤疾病中的治疗潜力,以期为CBD作为皮肤病的新疗法提供参考。
Abstract:
Cannabidiol(CBD)is one of the most abundant cannabinoids in industrial cannabis plants.Because of its absence of psychoactive properties and exciting clinical trial results,now FDA has approved it for the treatment of refractory epilepsy.Its benefits for inflammatory and hyperproliferative disorders have also been demonstrated. Additionally,recent studies indicated potential applications of CBD in dermatology,including acne,dermatitis,psoriasis,and skin tumors.In this context,this article reviews the targets and potential applications of CBD in the treatments of dermatoses,providing a reference for CBD as a novel option for skin diseases.

参考文献/References:

[1] Pisanti S,Malfitano AM,Ciaglia E,et al.Cannabidiol:State of the art and new challenges for therapeutic applications [J].Pharmacol Ther,2017,175:133-150.
[2] Millar SA,Stone NL,Yates AS,et al.A systematic review on the pharmacokinetics of cannabidiol in humans [J].Front Pharmacol,2018,9:1365.
[3] Taylor L,Gidal B,Blakey G,et al.A phase I,randomized,double-blind,placebo-controlled,single ascending dose,multiple dose,and food effect trial of the safety,tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects [J].CNS Drugs,2018,32(11):1053-1067.
[4] Giacoppo S,Galuppo M,Pollastro F,et al.A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis [J].Daru,2015,23:48
[5] Fernándezruiz J,Sagredo O,Pazos MR,et al.Cannabidiol for neurodegenerative disorders:important new clinical applications for this phytocannabinoid? [J].Br J Clin Pharmacol,2013,75(2):323-333.
[6] Elmes MW,Kaczocha M,Berger WT,et al.Fatty acid-binding proteins(FABPs)are intracellular carriers for Δ9-tetrahydrocannabinol(THC)and cannabidiol(CBD)[J].J Biol Chem,2015,290(14):8711-8721.
[7] Caterina MJ.TRP channel cannabinoid receptors in skin sensation,homeostasis,and inflammation [J].ACS Chem Neurosci,2014,5(11):1107-1116.
[8] 项蕾红.中国痤疮治疗指南(2014修订版)[J].临床皮肤科杂志,2015,44(1):52-57.
[9] Oláh A,Tóth BI,Borbíró I,et al.Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes [J].J Clin Invest,2014,124(9):3713-3724.
[10] Oláh A,Bíró T.Targeting cutaneous cannabinoid signaling in inflammation-A “high”-way to heal? [J].Ebiomedicine,2017,16:3-5.
[11] Petrosino S,Verde R,Vaia M,et al.Anti-inflammatory properties of cannabidiol,a nonpsychotropic cannabinoid,in experimental allergic contact dermatitis [J].J Pharmacol Exp Ther,2018,365(3):652-663.
[12] Wilkinson JD,Williamson EM.Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis [J].J Dermatol Sci,2007,45(2):87-92.
[13] Pucci M,Rapino C,Di Francesco A,et al.Epigenetic control of skin differentiation genes by phytocannabinoids [J].Br J Pharmacol,2013,170(3):581-591.
[14] Hegde VL,Singh UP,Nagarkatti PS,et al.Critical role of mast cells and peroxisome proliferator-activated receptor γ in the induction of myeloid-derived suppressor cells by marijuana cannabidiol in vivo [J].J Immunol,2015,194(11):5211-5222.
[15] Kozela E,Juknat A,Gao F,et al.Pathways and gene networks mediating the regulatory effects of cannabidiol,a nonpsychoactive cannabinoid,in autoimmune T cells [J].J Neuroinflammation,2016,13(1):136.
[16] 陈丹萍,魏志平,吴倩,等.大麻二酚对HaCaT细胞分泌IL-8及IL-10的影响 [J].中国麻风皮肤病杂志,2013,29(8):496-498.
[17] Chakravarti B,Ravi J,Ganju RK.Cannabinoids as therapeutic agents in cancer:current status and future implications [J].Oncotarget,2014,5(15):5852-5872.
[18] Armstrong JL,Hill DS,Mckee CS,et al.Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death [J].J Invest Dermatol,2015,135(6):1629-1637.
[19] Simmerman E,Qin X,Yu JC,et al.Cannabinoids as a potential new and novel treatment for melanoma:A pilot study in a murine model [J].J Surg Res,2019,235:210-215.
[20] Solinas M,Massi P,Cantelmo AR,et al.Cannabidiol inhibits angiogenesis by multiple mechanisms [J].Br J Pharmacol,2012,167(6):1218-1231.
[21] Chelliah MP,Zinn Z,Khuu P,et al.Self-initiated use of topical cannabidiol oil for epidermolysis bullosa [J].Pediatr Dermatol,2018,35(4):e224-e227.
[22] Schräder NHB,Duipmans JC,Molenbuur B,et al.Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa:a report of three cases [J].Br J Dermatol,2019,18(4):922-924.
[23] Hwang YS,Kim YJ,Kim MO,et al.Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK [J].Chem Biol Interact,2017,273:107-114.
[24] Iffland K,Grotenhermen F.An update on safety and side effects of cannabidiol:A review of clinical data and relevant animal studies [J].Cannabis Cannabinoid Res,2017,2(1):139-154.
[25] Carty DR,Miller ZS,Thornton C,et al.Multigenerational consequences of early-life cannabinoid exposure in zebrafish [J].Toxicol Appl Pharmacol,2019,364:133-143.
[26] Robinson E,Murphy E,Friedman A.Knowledge,attitudes,and perceptions of cannabinoids in the dermatology community [J].J Drugs Dermatol,2018,17(12):1273-1278.

备注/Memo

备注/Memo:
[作者单位] 四川大学华西医院皮肤性病科,四川 成都 610041
[通讯作者] 蒋献,E-mail:jennyxianj@163.com
更新日期/Last Update: 2019-09-12